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Carroll CC, Dickinson JM, LeMoine JK, Haus JM, Wein-
heimer EM, Hollon CJ, Aagaard P, Magnusson SP, Trappe TA.
Influence of acetaminophen and ibuprofen on in vivo patellar
tendon adaptations to knee extensor resistance exercise in older
adults. J Appl Physiol 111: 508 –515, 2011. First published May
19, 2011; doi:10.1152/japplphysiol.01348.2010.—Millions of
older individuals consume acetaminophen or ibuprofen daily and
these same individuals are encouraged to participate in resistance
training. Several in vitro studies suggest that cyclooxygenase-
inhibiting drugs can alter tendon metabolism and may influence
adaptations to resistance training. Thirty-six individuals were ran-
domly assigned to a placebo (67  2 yr old), acetaminophen (64 
1 yr old; 4,000 mg/day), or ibuprofen (64  1 yr old; 1,200
mg/day) group in a double-blind manner and completed 12 wk of
knee extensor resistance training. Before and after training in vivo
patellar tendon properties were assessed with MRI [cross-sectional
area (CSA) and signal intensity] and ultrasonography of patellar
tendon deformation coupled with force measurements to obtain
stiffness, modulus, stress, and strain. Mean patellar tendon CSA
was unchanged (P  0.05) with training in the placebo group, and
this response was not influenced with ibuprofen consumption.
Mean tendon CSA increased with training in the acetaminophen
group (3%, P  0.05), primarily due to increases in the mid (7%,
P  0.05) and distal (8%, P  0.05) tendon regions. Correspond-
ingly, tendon signal intensity increased with training in the acet-
aminophen group at the mid (13%, P  0.05) and distal (15%, P 
0.07) regions. When normalized to pretraining force levels, patellar
tendon deformation and strain decreased 11% (P  0.05) and
stiffness, modulus, and stress were unchanged (P  0.05) with
training in the placebo group. These responses were generally
uninfluenced by ibuprofen consumption. In the acetaminophen
group, tendon deformation and strain increased 20% (P  0.05)
and stiffness (17%, P  0.05) and modulus (20%, P  0.05)
decreased with training. These data suggest that 3 mo of knee
extensor resistance training in older adults induces modest changes
in the mechanical properties of the patellar tendon. Over-the-
counter doses of acetaminophen, but not ibuprofen, have a strong
influence on tendon mechanical and material property adaptations
to resistance training. These findings add to a growing body of
evidence that acetaminophen has profound effects on peripheral
tissues in humans.
stiffness; modulus; strain; cross-sectional area
TENDONS are an integral part of normal musculoskeletal func-
tion, and changes in tendon elastic properties can influence
muscle force transmission to bone (4), energy conservation
during locomotion, and joint position control (cf. 3, 22).
Tendon strength is largely determined by the composition of
the extracellular matrix (ECM), which consists mainly of type
I collagen. In humans, acute exercise increases tendon collagen
synthesis (23), which presumably contributes to chronic exer-
cise adaptations such as tendon hypertrophy (10, 14, 32) and
increased tendon stiffness (14, 17, 18, 29). These changes in
tendon properties likely contribute to the improvements in
physical function associated with exercise training in young
and old individuals.
Interestingly, a substantial amount of data suggests that
cyclooxygenase (COX)-inhibiting drugs may alter tendon
ECM metabolism (1, 5, 19, 31, 40–42, 44), which could limit
tendon adaptations to exercise. COX enzymes are the rate-
limiting step in the conversion of arachidonic acid to various
prostaglandins, which regulate a variety of processes including
inflammation and pain (37). For this reason COX-inhibiting
drugs such as ibuprofen and acetaminophen are consumed
daily by millions of individuals for musculoskeletal pain and
chronic arthritic conditions. Inhibition of COX activity de-
creases resting and postexercise prostaglandin production and
blood flow in human Achilles tendon (19), inhibits collagen
synthesis in animal tendon (6), and inhibits proliferation of
tendon fibroblasts in in vitro cell culture models (31, 40–42).
In nontendon connective tissue, prostaglandins influence ECM
remodeling via regulating the activity of the same collagen
degrading enzymes (matrix metalloproteinases) seen in tendon
(24, 25) and COX inhibition increases expression of these
enzymes (44). Therefore, these drugs, when taken during
exercise training, may alter the tendon adaptations (increased
stiffness and modulus, and decreased strain) previously dem-
onstrated with chronic resistance exercise in older individuals
(29), and ultimately might limit improvements in physical
function. The potential effect of these drugs is especially
important for older individuals, who are encouraged to exercise
to improve health but are also commonly using COX-inhibiting
drugs on a daily basis. Further, aging itself results in a change
in ECM structure and a region-specific decline in patellar
tendon size and signal intensity (1, 7, 9), changes which may
be exacerbated by consumption of COX-inhibiting drugs dur-
ing exercise training.
We evaluated the influence of daily ibuprofen and acetamin-
ophen use on the in vivo properties of the patellar tendon using
magnetic resonance imaging (MRI) and ultrasonography cou-
pled with tendon force measurements before and after 12 wk of
resistance training in older humans. We hypothesized that
consumption of the COX-inhibiting drugs ibuprofen (1,200
mg/day) and acetaminophen (4,000 mg/day) during 12 wk of
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knee extensor resistance training would limit the increase in
tendon stiffness and Young’s modulus previously reported (29)
with resistance training in individuals not consuming these
drugs.
METHODS
Overall Study Design
This study was a randomized, placebo-controlled, double-blind
12-wk investigation. During the 12 wk subjects completed a progres-
sive resistance-training program of the knee extensors three times per
week and consumed a placebo, acetaminophen, or ibuprofen. The
study was conducted at the Ball State University Human Performance
Laboratory and Ball Memorial Hospital and approved by the Institu-
tional Review Boards of both institutions. All of the procedures, risks,
and benefits associated with the study were explained to the subjects
before giving written consent to participate. This study was a part of
another investigation (36) evaluating the influence of acetaminophen
and ibuprofen consumption during chronic resistance training on
skeletal muscle adaptations.
Subjects
Men and women were recruited from the greater Muncie, IN, area.
Subjects completed a medical screening exam, which included routine
blood and urine clinical chemistries, a resting and exercise electro-
cardiogram, and a detailed health and exercise history questionnaire.
Subjects were excluded if they had any cardiac, orthopedic (e.g.,
patellar tendinopathy), or neuromuscular conditions that would pre-
Table 1. Subject characteristics, intervention compliance,
and resistance training parameters
Subject Characteristics Placebo Acetaminophen Ibuprofen
n 12 11 13
M/F 8/4 7/4 9/4
Agea, yr 67  2 64  1 64  1
Age range, yr 60–78 60–71 60–77
Heighta, cm 170  3 172  5 175  2
Weight, kg 77.3 4.4 93.1  5.6* 82.6  2.8
Intervention complianceb
Drug consumption, %
Observeda 93  2 93  2 94  2
Reporteda 100  0.1 99  1 99  0.3
Exercise traininga, % 100 100 100
Resistance training
Mean traininga, %1RM 74  1 71  1 73  1
Mean training loada, kg 58  7 55  6 56  4
Data expressed as means  SE; M, male; F, female; 1RM, one repetition
maximum. Observed is that directly viewed by the research staff in person or
on personal digital video. Reported is based on the number of doses remaining
in the returned pillboxes. The 6–7% “noncompliance” with the observed
compliance was primarily due to technical issues with the personal digital
video cameras (8). %Exercise training compliance is the percentage of the 36
scheduled exercise training sessions completed by the subjects. *Significant
difference from placebo, P 0.05. aNo significant difference among values for
all three groups, P  0.05. b%Drug consumption compliance is the percentage
of the 252 scheduled doses consumed by the subjects.
Fig. 1. Sagittal (A) and axial (b–d) MRI images of
the patellar tendon. Sagital images (TR/TE  400/
14, spin echo; ETL  0; NEX  2; PPFOV  100;
FOV  16  16 cm, 256  256 matrix; slice
thickness  4 mm; spacing  0 mm) were used for
the tendon length measurement, represented by the
solid white line. Axial images (TR/TE  550/12.4,
fast spin echo train; ETL  3; NEX  3; PPFOV 
100; FOV  16  16 cm, 256  256 matrix; slice
thickness  4 mm; spacing  0 mm) were used for
the patellar tendon cross-sectional area (CSA) mea-
surements at the proximal (B), mid (C), and distal (D)
tendon, represented by the white line outlining the
tendon in all 3 images. The knee joint was in slight
flexion for all imaging.
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clude them from participating in a resistance exercise training pro-
gram, abnormal blood or urine chemistries, arthritis, diabetes, uncon-
trolled hypertension, or any condition that would be a contraindication
to taking acetaminophen or ibuprofen for 3 mo, if they were chroni-
cally consuming any prescription or non-prescription COX-inhibiting
drugs, if they were involved in any formal aerobic or resistance
exercise training program, if they smoked, or if they were60 or85
yr of age.
Sixty-one individuals consented to be screened for participation in
this study, 17 were excluded due to medical reasons, and 7 decided
not to participate for personal reasons. During training one individual
sustained a back injury unrelated to the study and was unable to
complete the resistance training. Subject characteristics of the 36 men
and women included in the study are presented in Table 1.
Interventions
Resistance exercise training protocol. All subjects completed a
progressive resistance training program consisting of bilateral knee
extension (36). Each subject was scheduled for resistance training on
an isotonic knee extension device (Cybex Eagle, Medway, MA) three
times per week for 12 wk for a total of 36 sessions. All sessions were
supervised by a member of the research team. Each session was
separated by at least 1 day and consisted of 5 min of light cycling
(model 828E, Monark Exercise AB, Vansbro, Sweden), two sets of
five knee extensions at a light weight, followed by three sets of 10
repetitions with 2 min of rest between sets. Training intensity was
based on each individual’s one repetition maximum (1RM) and was
adjusted during the training based on each individual’s training
session performance and biweekly 1RM. Data on resistance training
performance and compliance are presented in Table 1 and in Trappe
et al. (36).
Cyclooxygenase-inhibitor consumption. Drugs were administered
over the 12 wk in double-blind, placebo-controlled fashion as we have
previously described (8, 39). Each drug was administered in three
doses per day (8 AM, 2 PM, 8 PM) corresponding to the
maximal over-the-counter daily dose (acetminophen: 4,000 mg total;
ibuprofen: 1,200 mg total). The placebo group was given an identical
number of pills/dose (three), which were indistinguishable from the
drug doses. Each subject was given their doses in weekly batches (21
doses) in pillboxes labeled with the date and consumption time.
Subjects were instructed to not consume any other COX-inhibiting
drugs outside of the study. Adherence to the study drug regimen was
monitored as previously described (8) and compliance to study med-
ication is reported in Table 1 and elsewhere (36).
Potential side effects of drug consumption were monitored via
monthly blood draws for renal (creatinine), hepatic (alanine amino-
transferase), and hematologic (hematocrit) measures, which were
unchanged in all three groups (36).
Magnetic Resonance Imaging
In conjunction with the thigh skeletal muscle scanning (36), axial
and sagittal images of the patellar tendon were obtained using MRI as
previously described (7). After 1 h of lying supine [to control for fluid
shifts in skeletal muscle (36)], each subject’s right knee was placed in
an extremity coil (GE 1.5T, Quadrature Lower Extremity Coil
472GE-64, Invivo, Pewaukee, WI; Fig. 1). A plastic tube containing
1.0% CuSO4 was placed in the field of view for normalization of
tendon signal intensity (tendon signal intensity/CuSO4 signal inten-
sity). Sagittal images were obtained beginning on the lateral most
portion of the lateral condyle of the tibia, then moving medially. Axial
images of the patellar tendon were obtained beginning 8 mm (two
slices) proximal of the distal pole of the patella and proceeding
Table 2. Mean tendon CSA and signal intensity
Placebo Acetaminophen Ibuprofen
Pre Post Pre Post Pre Post
CSA, mm2 117.1  10.1 115.1 9.6 124.4 13.1 127.9 13.0* 122.8 8.5 124.2 8.5
Signal intensity, MGV 18.4 1.0 18.3 1.2 18.9 1.5 20.2 1.5 20.4 0.6 20.8 1.6
Data expressed as means  SE; CSA, cross-sectional area; Pre, pretraining; Post, posttraining; MGV, mean gray value in arbitrary units. *P  0.05, increase
with training.
Fig. 2. Ultrasound image of the patellar tendon
taken at rest (A) and during a 10-s isometric
“ramped” contraction (B) with the knee joint at
90°. Dashed line indicates patella and tibia posi-
tion before contraction, and solid line indicates
patella and tibia position after contraction, the
difference representing patellar tendon deforma-
tion.
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distally. For tendon length, sagittal images (Fig. 1A) were reviewed
with OsiriX (version 2.7.5) and only slices with complete tendon from
the distal pole of the patella to tibial insertion were chosen for
analysis. ImageJ (version 1.34) was then used to determine tendon
length via manual planimetry.
Using the axial scans, tendon cross-sectional area (CSA) and signal
intensity [mean gray value (MGV)] were determined by manually
circumscribing the patellar tendon using ImageJ. The value of all
slices from proximal to distal was averaged to determine mean tendon
CSA and signal intensity. Region-specific CSA and signal intensity
(Fig. 1, B–D) were determined as we have previously described (7).
The reliability of this method in our laboratory has been reported
previously (7). All measurements were performed by the same inves-
tigator.
MRI of the patellar tendon was performed on all 36 individuals
(Table 1); however, two individuals were excluded from analysis
because their knee would not adequately fit in the knee coil, another
individual had a severe claustrophobic response and was unable to
complete the tendon scans, and errors during data acquisition pre-
vented the inclusion of tendon scans from two individuals. Addition-
ally, due to an MRI software upgrade that occurred during the study,
a different knee coil (GP Flex Coil) was temporarily used. Although
this coil did not influence our tendon CSA and length measurements,
it did alter the signal intensity. Therefore, we are only able to report
CSA data on 31 individuals [placebo: n  11, 7 males (M)/4 females
(F); acetaminophen: n 10, 6 M/4 F; ibuprofen: n 10, 6 M/4 F] and
signal intensity data on 21 individuals (placebo: n  8, 6 M/2 F;
acetaminophen: n  8, 4 M/4 F; ibuprofen: n  5, 3 M/2 F).
Patellar Tendon Mechanical Properties
Patellar tendon mechanical properties were assessed as previously
described (7, 9, 11, 14). Briefly, subjects were firmly strapped into a
rigid aluminum chair with the knee joint at 90° of flexion. A mini-
mally padded cuff was attached to their lower leg 3 cm proximal to
the medial malleolus. Subjects performed several “ramped” 10-s
isometric quadriceps contractions to maximal effort with 90-s rest
between contractions (7, 9, 11, 14). Force was recorded via a strain-
gauge load cell (Omegadyne, LC101–500) interfaced with a personal
computer (Gateway E-4200). An ultrasound probe (7.5 MHz, 70-mm
B-mode linear array, Sonoline Sienna, Siemens, Erlangen, Germany)
was mounted sagittally on the skin overlying the patellar tendon to
monitor displacement of both the patella and tibia during the
“ramped” isometric effort [Fig. 2, (7, 9, 11, 14)]. Video feed from the
ultrasound unit was captured on a personal computer (Matrox Inspec-
tor, Matrox Electronic Systems, Dorval, Quebec, Canada) in syn-
chrony with recording of the instantaneous knee extensor moment. All
participants completed three sessions, one familiarization and two
testing sessions both pre- and posttraining. Displacement of the patella
and tibia (Fig. 2) were determined with custom-designed software
(21), and deformation was defined as the change in distance between
the tibia and patella (7, 9, 11, 14). Tendon force was calculated by
dividing the measured knee extension moment by the internal moment
arm [estimated from femur length (7, 9, 11, 14, 43)].
Two comparisons of mechanical properties were made: 1) peak
force: mechanical properties (pre- and posttraining) were determined
from the two attempts from which the highest tendon force was
achieved. The data generated (force, deformation, stiffness, modulus,
stress, and strain) from these two attempts were then averaged; and
2) force-normalized: deformation for all “ramped” contractions was
determined and the two contractions with the highest and lowest
deformation within a given testing session were excluded. This
approach was repeated for the posttraining data and then all attempts
(pre and post) were analyzed to the greatest common force for each
individual subject.
Force-deformation curves were fit with a second-order polynomial
and any curves with r2  0.97 were excluded from analysis. Tendon
variables (stiffness, modulus, stress, strain) were calculated as previ-
ously described (7). The reliability of this method in our laboratory
has been reported previously (7). The same investigator performed all
mechanical analyses. Testing of in vivo patellar tendon mechanical
properties was conducted on a subset of individuals (placebo: n  7,
6 M/1 F; acetaminophen: n  7, 4 M/3 F; ibuprofen: n  8, 5 M/3 F)
who participated in the 12 wk of resistance training.
Statistics
All data were first tested for normality using a Shapiro-Wilk test
(P 0.05). Pre- to posttraining data that fit a normal distribution were
evaluated using a two-way (drug and time) repeated-measures
ANOVA. A one-way ANOVA was used to evaluate any differences
in subject characteristics, training intensity, drug compliance, and
percent change in tendon CSA, signal intensity, and mechanical
properties with training. The Student-Newman-Keuls post hoc test
was used to explore differences when a significant interaction was
detected.
For pre-post training data that failed normality testing, a rank or
log10 transformation was performed, and the transformed data were
assessed with a two-way (drug and time) repeated-measures ANOVA.
Table 3. Regional tendon CSA
Placebo Acetaminophen Ibuprofen
Pre Post Pre Post Pre Post
Proximal 139.0 14.0 135.5  14.1 145.8  11.0 146.2 11.1 140.1 9.8 143.9 10.1
Mid 111.4 9.1 109.8  8.7 121.0  13.5 128.7 14.3* 119.8 9.7 115.7 9.4
Distal 107.5 8.3 107.9  8.7† 110.8  15.1 118.1 14.9† 131.3 9.1 133.4 7.7†
Data expressed as means  SE of CSA in mm2. *P  0.05, increase with training. †P  0.05, increase with training independent of drug group.
Fig. 3. Percent change in patellar tendon CSA at the proximal, mid, and distal
regions of the patellar tendon. *P  0.05, acetaminophen vs. placebo and
ibuprofen. †P  0.05, acetaminophen vs. placebo.
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A Kruskal-Wallis one-way ANOVA on Ranks with Dunn’s post hoc
test was used to evaluate any other data that failed normality testing.
Values were considered significant at an alpha level of P  0.05. All
data are expressed as means  SE. All data were analyzed using
SigmaPlot Version 11 (Systat Software).
RESULTS
Patellar Tendon CSA and MRI Signal Intensity
Mean patellar tendon CSA and CSA at the proximal and mid
regions of the tendon were unchanged (P  0.05) from pre- to
post-training in the placebo group, and this response was not
influenced with ibuprofen consumption (Tables 2 and 3,
Fig. 3). Distal tendon CSA increased with training across all
three groups but this increase was driven primarily by the
acetaminophen group (Fig. 3 and Table 3). Mean tendon CSA
was increased with training in the acetaminophen group (3 
1%, P  0.05), primarily due to increases in the mid (7  3%,
P  0.05) and distal (8  2%, P  0.05) regions of the tendon
(Tables 2 and 3, Fig. 3). Correspondingly, patellar tendon
signal intensity increased from pre- to posttraining in the
acetaminophen group at the mid (13  5%, P  0.05) and
distal (15  4%, P  0.07) regions of the tendon (Table 4).
There was no change from pre- to posttraining in tendon signal
intensity at any region in the placebo or ibuprofen groups
(Table 4). Resting patellar tendon length did not change (P 
0.05) from pre- to posttraining in any group (placebo: pre
45.1  1.5, post 45.1  1.4 mm; acetaminophen: pre 45.6 
2.3, post 45.1  2.2 mm; ibuprofen: pre 45.1  1.4, post
44.5  1.4 mm).
Patellar Tendon Mechanical Properties
Patellar tendon mechanical properties at peak tendon force
are presented in Table 5 and Fig. 4. Patellar tendon stress at
peak tendon force increased with training across all three
groups (P 0.05). Patellar tendon deformation and strain were
unchanged (P  0.05) from pre- to posttraining in the placebo
group, and this response was not influenced with ibuprofen
consumption. Conversely, in the acetaminophen group patellar
tendon deformation and strain at peak force increased (P 
0.05) with training by 24  8% and 31  13%, respectively.
Force-normalized patellar tendon mechanical properties are
presented in Table 6 and Fig. 5. Deformation decreased with
training in the placebo (11  5%, P  0.05) and ibuprofen
groups (10  5%, P  0.07). Strain also decreased in the
placebo group (11  5%, P  0.05) but not in the group
consuming ibuprofen. Patellar tendon stiffness and modulus
were unchanged by resistance training in the placebo and
ibuprofen groups. In contrast, stiffness (17  8%) and
modulus (20  7%) decreased (P  0.05) with training in
the group consuming acetaminophen. Patellar tendon deforma-
tion and strain increased (P  0.05) with training by 20  8%
and 20  9%, respectively, in the acetaminophen group.
DISCUSSION
To our knowledge this is the first investigation to study the
influence of ibuprofen (1,200 mg/day) or acetaminophen
(4,000 mg/day) consumption during resistance training on in
vivo tendon properties in older humans. The main findings
from the study were that 12 wk of knee extensor resistance
training only (placebo group) had a modest impact on the
mechanical properties of the patellar tendon and no impact on
the size or MRI signal intensity. Similar responses to the
resistance training were observed in the ibuprofen group,
suggesting that ibuprofen (1,200 mg/day) did not interfere with
the patellar tendon adaptations to resistance training. In con-
trast, daily acetaminophen consumption during resistance
training resulted in patellar tendon hypertrophy and MRI signal
intensity changes, along with changes in tendon mechanical
properties, none of which were consistent with the placebo
group.
Our initial impetus to examine the patellar tendon properties
in conjunction with our study on the effects of COX-inhibiting
drugs on skeletal muscle (36) was based on the results of
Reeves et al. (29) that demonstrated significant changes in the
Table 4. Regional tendon signal intensity (MGV)
Placebo Acetaminophen Ibuprofen
Pre Post % Pre Post % Pre Post %
Proximal 22.9  0.6 22.7  0.7 1  3 23.9  2.0 24.5 1.8 4 3 22.7  0.9 22.9 1.6 1  7
Mid 17.8  1.1 17.6  1.6 3  3 17.8  2.1 20.0 2.4* 13 5† 20.3 0.7 19.0 1.5 6  7
Distal 13.0  1.1 12.9  1.2 1  5 13.0  1.4 14.6 1.3‡ 15 4 16.9  1.5 18.5 3.5 8  14
Data expressed as means  SE of MGV in arbitrary units. *P  0.05, increased with training. †P  0.05, acetaminophen vs. placebo and ibuprofen. ‡P 
0.07, increase with training.
Table 5. Patellar tendon mechanical properties at peak tendon force
Placebo Acetaminophen Ibuprofen
Pre Post Pre Post Pre Post
Tendon force, N 3622  387 4271 371* 3464 756 4010 963* 2422  233 2829  255*
Deformation, mm 2.82 0.31 2.83 0.29 2.46 0.35 2.95 0.42† 2.81  0.20 2.57  0.19
Stiffness, N/mm 2,928  381 3,335 385‡ 3,313 417 3,078 480 2,053  213 2,590  310†
Modulus, GPa 1.03 0.12 1.22 0.13† 1.23 0.06 1.07 0.09 0.73  0.07 0.89  0.10§
Stress, MPa 30.4 3.9 37.1 3.6* 26.8 3.4 27.4 4.5* 18.9  2.4 21.4  1.9*
Strain, % 6.5  0.7 6.5 0.6 5.2 0.5 6.5 0.7† 6.1  0.4 5.6  0.4
Data expressed as means  SE. *P  0.05, increase with training independent of drug group; †P  0.05, increase with training, ‡P  0.08, increase with
training, §P  0.07, increase with training.
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mechanical properties of the patellar tendon after 14 wk of
knee extensor resistance training in older men and women.
Their findings (29) of a decrease in deformation and strain and
no change in stress or tendon CSA are in general agreement
with our common force data in the placebo group [maximal
tendon force did not change significantly from pre- to post-
training in their study (29)]. However, they (29) did show a
substantial increase in tendon stiffness and modulus (65–69%),
which were unchanged in the present study. These differences
may be due to methodological differences in the ultrasound
measurements that have been outlined previously (10, 11, 26).
The placebo group data should be considered in the context
of what happens to the patellar tendon with aging (7, 9) and
with resistance exercise training in young individuals (13–16,
20, 34). In general it appears that with aging patellar tendon
mechanical properties do not change (7, 9), but resistance
exercise training in young individuals does seem to have some
impact, albeit sometimes minor, on patellar tendon mechanical
properties (13–16, 20, 34). The degree of training impact may
be related to the duration (weeks, months, or years) or type of
training employed. Further, aging appears to have little effect
on the average patellar tendon CSA (7, 9), but may cause
region-specific tendon atrophy (7). Resistance training does
cause region-specific hypertrophy of the patellar tendon in
young individuals (14, 34), but this finding is not universal (15,
16). Finally, the material properties, estimated with MRI signal
intensity (7) and measured directly with biopsy measurements
of collagen and cross-linking (9), are altered with aging.
Studies in healthy young individuals show chronic resistance
training does not alter the patellar tendon collagen content or
cross-linking (20). Based on the aforementioned data and those
of Reeves et al. (29) our findings from the placebo group of a
modest change in some of the patellar tendon mechanical
properties and lack of change in the size and material proper-
ties (MRI signal intensity) are reasonable and for the most part
expected.
We have previously shown profound effects of both acet-
aminophen and ibuprofen on skeletal muscle prostaglandin
production, protein synthesis, and hypertrophy following re-
sistance exercise (36, 38, 39). These findings are in contrast to
the findings from the present study in which ibuprofen did not
appear to have any substantial impact on the tendon mechan-
ical properties or any of the MRI measurements of CSA and
signal intensity, as the responses in the ibuprofen group basi-
cally mirrored the placebo group. The only difference between
the placebo and ibuprofen groups was a lack of significant
reduction in strain in the ibuprofen group following training
(Tables 5 and 6). Given the overall similar responses observed
in both groups, it is unlikely this reflects a significant influence
of ibuprofen on the tendon adaptations to training and suggests
the effects of ibuprofen and acetaminophen may be tissue
specific (tendon vs. skeletal muscle), a potentially important
consideration for physicians when prescribing these medica-
tions.
Fig. 4. Percent change in patellar tendon mechanical properties at peak tendon
force. *P  0.05, acetaminophen vs. placebo and ibuprofen. †P  0.05,
acetaminophen vs. ibuprofen. §P  0.057, acetaminophen vs. placebo.
Table 6. Patellar tendon mechanical properties normalized to a common tendon force
Placebo Acetaminophen Ibuprofen
Pre Post Pre Post Pre Post
Deformation, mm 2.62 0.31 2.29 0.25* 2.14 0.24 2.56 0.32† 2.51  0.21 2.25  0.18‡
Stiffness, N/mm 2,668  362 2,723 379 2,948 315 2,480 406* 1,796  219 1,988  192
Modulus, GPa 0.93 0.11 0.96 0.11 1.11 0.05 0.88 0.07* 0.64  0.08 0.66  0.07
Stress, MPa 25.1 2.8 25.4 2.5 21.6 1.8 20.9 1.8* 14.9  1.9 14.8  1.8
Strain, % 6.0  0.7 5.2 0.5* 4.6 0.4 5.5 0.6† 5.4  0.4 4.9  0.3
Data expressed as means  SE; *P  0.05, decrease with training. †P  0.05, increase with training. ‡P  0.07, decrease with training.
Fig. 5. Percent change in patellar tendon mechanical properties compared at a
common tendon force. *P  0.05, acetaminophen vs. placebo and ibuprofen,
†P  0.05, acetaminophen vs. ibuprofen.
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The acetaminophen group, however, was impacted by the
daily consumption of acetaminophen during the 12 wk of
resistance training. Patellar tendon CSA increased with train-
ing, which would be expected to increase tendon stiffness and
reduce strain. In contrast, we observed a large increase in strain
with decreased stiffness. The magnitude of this effect was
substantial considering a similar increase in gastrocnemius
tendon strain was reported after 90 days of unloading and
inactivity due to bed rest (28). A corresponding reduction in
tendon elastic modulus in the acetaminophen group suggests
that the internal structure of the tendon may have been altered,
a conclusion supported by the change in MRI signal intensity
observed in the acetaminophen group (Table 4). We can only
speculate as to the changes in the tendon that may have
occurred in the acetaminophen group; however, changes in
MRI signal intensity have been correlated to histological find-
ings and may indicate changes in the ECM tissue hydration, or
collagen fiber structure (35). In support of this notion, we have
shown that changes in biopsy-derived skeletal muscle tissue
protein content corresponded with changes in skeletal mus-
cle MRI signal intensity over a 3-mo exercise-training
program in older individuals (12). Whatever the cause of the
altered tendon mechanical properties, it is clear that the
increased CSA is not improving mechanical properties in
the acetaminophen group, as would be expected if changes
in tendon material properties were proportional to the in-
crease in tendon CSA. Based on the current findings, it
could be suggested that long-term acetaminophen consump-
tion might predispose individuals to tendinopathy (30, 33)
or impact the rate of torque development during muscle
contraction (4). In contrast, some of the adaptations, such as
a reduction in tendon stiffness and modulus, might be
beneficial for diabetics where contracture of the Achilles
tendon may contribute to foot deformities and ulcer forma-
tion (2, 27). Finally, if acetaminophen is altering tendon
ECM metabolism then it seems likely that these effects
would not be limited to the tendon. Many tissues rely on an
extensive collagen matrix for support and effective force
transfer (e.g., bone). Thus future investigations should con-
sider the possible impact of acetaminophen on this and other
tissues.
In conclusion, we have demonstrated that acetaminophen
(4,000 mg/day) but not ibuprofen (1,200 mg/day) taken orally
during 12 wk of knee extensor resistance training in humans
results in tendon hypertrophy but decreased tendon stiffness
and increased strain. The significance of these findings is wide
ranging and could impact how acetaminophen it utilized clin-
ically. Our findings further highlight the profound effect of
acetaminophen on peripheral tissues in vivo (36, 38, 39) and
have important implications for the millions of individuals who
consume acetaminophen daily for painful musculoskeletal and
arthritic conditions, tendinopathy, and other soft tissue injuries.
Although further studies are needed to evaluate why acetamin-
ophen altered tendon mechanical properties in the present
study, our data add to a growing body of literature challenging
the traditional view that acetaminophen has little effect on
peripheral tissues.
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